Co-Authors
This is a "connection" page, showing publications co-authored by APAR PATAER and LAUREN AVERETT BYERS.
Connection Strength
0.192
-
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).
Score: 0.062
-
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
Score: 0.056
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
Score: 0.048
-
Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 2012; 7(2):e31087.
Score: 0.026